Showing 1 posts of 1 posts found.
Shares at Infinity Pharmaceuticals (NASDAQ: INFI) fell around 70% upon the announcement of new Phase II data for their non-Hodgkin …
NICE recommends daratumumab quadruplet for newly diagnosed multiple myeloma
AstraZeneca’s Trixeo approved in EU for asthma
Amplio reports early human data for novel methotrexate approach in rheumatoid arthritis
Survodutide delivers up to 13.1% weight loss in phase 3 obesity and diabetes trial
ESTEVE CDMO adds $17.5m to Illinois expansion